WaveMan
WaveMan · Company
CYRX · Cryoport, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CYRX Cryoport (CYRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001124524
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $168.0K priced

What the filings say about CYRX

Insiders, 180 days
-$4.1M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$426.8K
1 notice

Cryoport insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Cryoport, Inc. insiders sold a net $4.1M of stock across 121 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
SHELTON JERRELL
President, CEO
SELL
2026-08-11 SEC
28,800
$429.4K
+20.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Mar 23, 2026.
  • The trade is 2.4% of the 1,201,814 shares held after it.
  • No other insider sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO SHELTON JERRELL sold about $429.4K of CYRX on Aug 11, 2026; 103 funds added in the latest 13F quarter.
ZECCHINI EDWARD J
Chief Digital and Tech Officer
SELL
2026-06-12 SECtraded 2026-06-11
33,600
$486.2K
+20.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 10, 2026.
  • The trade is 30.6% of the 109,719 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Digital and Tech Officer ZECCHINI EDWARD J sold about $486.2K of CYRX on Jun 11, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
ZECCHINI EDWARD J
Chief Digital and Tech Officer
SELL
2026-06-12 SECtraded 2026-06-10
1,400
$21.3K
+20.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 16, 2026.
  • The trade is 1.3% of the 109,719 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Digital and Tech Officer ZECCHINI EDWARD J sold about $21.3K of CYRX on Jun 10, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
Mandalam Ramkumar
Director
SELL
2026-06-08 SEC
23,214
$358.4K
+17.1%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Dec 10, 2025.
  • The trade is 34.2% of the 67,894 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mandalam Ramkumar sold about $358.4K of CYRX on Jun 8, 2026; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
STEFANOVICH ROBERT
Chief Financial Officer
SELL
2026-06-08 SECtraded 2026-06-04
169,427
$2.8M
+17.1%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Mar 23, 2026.
  • The trade is 154.2% of the 109,850 shares held after it.
  • 2 other insiders sold within 30 days.
  • 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer STEFANOVICH ROBERT sold about $2.8M of CYRX on Jun 4, 2026, the largest insider sale at the company since 2023; 2 other insiders sold within 30 days and 103 funds added in the latest 13F quarter.
121 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 116 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.1M over 180 days
-$429.4K over 90 days
below 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
+12.4% year over year
more than 62% of Pharma & Biotech
Margin
44.4% net margin
more than 94% of Pharma & Biotech
Buybacks
$10.0M repurchased, FY to 2025-12-31
below 69% of Pharma & Biotech
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CYRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+67.4%12M
-27%+7%+40%+74%2025-102025-122026-022026-042026-062026-082026-10 2026-06-04 · STEFANOVICH ROBERT sold $2.8M2026-06-11 · ZECCHINI EDWARD J sold $486.2K2026-08-11 · SHELTON JERRELL sold $429.4K2026-06-08 · Mandalam Ramkumar sold $358.4K2026-03-12 · STEFANOVICH ROBERT sold $300.3K2025-12-10 · Mandalam Ramkumar sold $115.6K2026-03-16 · SHELTON JERRELL sold $63.3K2026-03-16 · Sawicki Mark W sold $25.9K2026-03-23 · SHELTON JERRELL sold $23.7K2026-03-16 · STEFANOVICH ROBERT sold $21.9K2026-06-10 · ZECCHINI EDWARD J sold $21.3K2026-03-16 · ZECCHINI EDWARD J sold $16.1K2026-03-23 · Sawicki Mark W sold $11.0K2026-03-23 · STEFANOVICH ROBERT sold $8.9K2026-08-11 · JERRELL W SHELTON filed to sell $426.8K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CYRX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,218,434 sh
$66.2M
CADIAN CAPITAL MANAGEMENT, LP
2,920,681 sh
$45.9M
First Eagle Investment Management, LLC
2,542,848 sh
$39.9M
Assenagon Asset Management S.A.
2,304,622 sh
$36.2M
MORGAN STANLEY
2,276,741 sh
$35.7M

Congress trades in CYRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CYRX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JERRELL W SHELTON
Filed 2026-08-11
$426.8K

CYRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Brown Capital Management Small Company Fund
$7.9M position · as of 2026-06-30
2.5%
ALGER SMALL CAP GROWTH FUND
$3.9M position · as of 2026-07-31
1.9%
ALGER SMALL CAP FOCUS FUND
$16.1M position · as of 2026-07-31
1.9%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND
$1.3M position · as of 2026-07-31
1.6%
Calamos Timpani Small Cap Growth Fund
$11.2M position · as of 2026-07-31
1.5%
Needham Small Cap Growth Fund
$5.9M position · as of 2026-06-30
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Shelton
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$2.2M
$1.5M
$1.0M
-6%
+41%
2022
$2.5M
-$7.4M
$1.1M
+5%
+45%
2021
$5.1M
$9.6M
$1.9M
+259%
+90%
2020
$5.5M
$15.8M
$1.8M
+167%
+36%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.1M sold by insiders over 180 days, 103 funds added last quarter, $426.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CYRX financials

Revenue growth
+12.4%
XBRL, annual
Net margin
44.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$186.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-20.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$20.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.38x
long-term debt only, 2025-09-30 (9 months older than the period end); equity 2026-06-30
Cash flow to debt
0.04x
TTM operating cash flow over long-term debt only, 2025-09-30 (9 months older than the period end)
Return on equity
-7.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-4.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-6.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$816.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2025-09-30 (9 months older than the period end), minus cash 2026-06-30
FCF yield
-2.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$176.2M$228.4M$233.3M$237.3M
Gross profit$83.1M$69.7M$75.3M$103.9M
Operating income-$36.8M-$121.7M-$100.5M-$31.9M
Net income$78.3M-$114.8M-$99.6M-$37.3M
EPS (diluted)1.40-2.49-2.21-0.93
Operating cash flow-$8.6M-$16.3M-$757.0K-$1.9M
Cash$250.5M$34.1M$35.2M$29.2M
Long-term debtn/a$183.9M$378.6M$406.7M
Buybacks$10.0Mn/an/a$38.0M
SEC XBRL, fiscal years, as known on 2026-10-28

CYRX Stock Sonar score 6/7 axes

Find similar shapesCompare

CYRX ranks highest on profitability (79th percentile) and risk and compliance (72nd), and lowest on insider conviction (10th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
79
Inputs
  • Return on equity-7.4% · 78 pct, sector of 545
  • Return on assets-4.9% · 78 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-6.2% · 81 pct, sector of 576
Financial health
55
Inputs
  • Debt to equity0.38x · 37 pct, sector of 352
  • Cash flow to debt0.04x · 73 pct, sector of 371
Growth
62
Inputs
  • Revenue growth, YoY+12.4% · 62 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
10
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.1M · 21 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
70
Inputs
  • Funds adding, latest quarter103 · 70 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
72
Inputs
  • Short interest, % of float+5.1% · 57 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+4.1% · 87 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CYRX filings, in plain words

Are Cryoport insiders buying or selling CYRX?

In the 180 days to 2026-10-28, Cryoport insiders were net sellers, a net $4.1M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of CYRX?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $426.8K of stock; the latest, by JERRELL W SHELTON, was filed 2026-08-11.

Read the full summary

In the 180 days to 2026-10-28, Cryoport insiders were net sellers of CYRX, a net $4.1M across purchases and sales reported on Form 4 by 4 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $426.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies